The CPI anti-CTLA-4 has been studied with immunocytokine therapy and an anti-GD2-IL-2 immunocytokine increased the efficacy of CTLA-4 CPI in melanoma models in a T cell-dependent manner. This evidence concerns the gene IL2 and melanoma.